Rubraca is a small molecule poly (ADP-ribose) polymerase (PARP) inhibitor developed by Clovis Oncology for the treatment of recurrent ovarian cancer patients with known BRCA mutations or other homologous recombination gene alterations.
PARP is an enzyme that plays an essential role in DNA repair mechanisms and homologous recombination events. PARP inhibitors act by directly blocking enzymatic activity, or by causing PARP to accumulate on DNA (PARP trapping), which results in DNA replication inhibition and cell death.
Tumor cells with BRCA1/2 gene mutations are dependent on PARP for DNA damage repair, and PARP inhibition selectively kills BRCA1- or BRCA2-deficient cells. As DNA repair is inhibited by PARP inhibitors, they are often sequenced after a cytotoxic chemotherapy which works by damaging DNA.
Key Topics Covered:
List of Figures
Figure 1: Rubraca for prostate cancer - SWOT analysis
Figure 2: Drug assessment summary of Rubraca for prostate cancer
Figure 3: Drug assessment summary of Rubraca for prostate cancer
Figure 4: Rubraca sales for prostate cancer across the US and five major EU markets, by country, 2017-26
Figure 5: Rubraca for ovarian cancer - SWOT analysis
Figure 6: Drug assessment of Rubraca for ovarian cancer
Figure 7: Drug assessment of Rubraca for ovarian cancer
List of Tables
Table 1: Rubraca drug profile
Table 2: Rubraca trials in prostate cancer
Table 3: Rubraca sales for prostate cancer across the US and five major EU markets, by country ($m), 2017-26
Table 4: Rucaparib drug profile
Table 5: Rubraca pivotal trial data in ovarian cancer
Table 6: Rubraca ongoing late-phase trials in ovarian cancer
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/jzwg26/rubraca?w=4